Ireland’s position on a slate of new EU pharmaceutical regulations is “evolving”. That’s according to the Department of Health as it continues to field a lobbying blitz from several major pharma firms with large operations in Ireland. The proposals are a major revamp of the EU’s existing framework for pharmaceuticals, which has been in place for 20 years. The reforms seek to improve the accessibility and affordability of medicines and reinforce supply chains in Europe to prevent any shortages of critical medicines. The measures also introduce stricter environmental-related policies around drug development. While the proposals were introduced in early 2023,…

Want to continue reading?

Introductory offer: Sign up today and pay €200 for an annual membership, a saving of €50.

Subscribe

Cancel at any time.

Are you already a member? .